Show simple item record

dc.contributor.authorPérez-Casas, C
dc.contributor.authorHerranz, E
dc.contributor.authorFord, N
dc.date.accessioned2008-02-07T17:04:06Z
dc.date.available2008-02-07T17:04:06Z
dc.date.issued2001-11
dc.identifier.citationPricing of drugs and donations: options for sustainable equity pricing. 2001, 6 (11):960-4 Trop. Med. Int. Healthen
dc.identifier.issn1360-2276
dc.identifier.pmid11703854
dc.identifier.urihttp://hdl.handle.net/10144/17744
dc.description.abstractEffective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines. Increasingly, drug donations have been established by drug companies, but these are often limited in time, place or use. Measures exist which are more sustainable and will have a greater positive impact on people's health. Principally, these are encouraging generic competition; adopting into national legislation and implementing TRIPS safeguards to gain access to cheaper sources of drugs; differential pricing; creating high volume or high demand through global and regional procurement; and supporting the production of quality generic drugs by developing countries through voluntary licenses if needed, and facilitating technology transfer.
dc.language.isoenen
dc.publisherWiley-Blackwell
dc.relation.urlhttp://www.blackwell-synergy.com/loi/tmi
dc.rightsArchived on this site with the kind permission of Wiley-Blackwellen
dc.subject.meshAnti-Bacterial Agentsen
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshAntiprotozoal Agentsen
dc.subject.meshDrug Costsen
dc.subject.meshDrug Industryen
dc.subject.meshDrugs, Genericen
dc.subject.meshHIV Infectionsen
dc.subject.meshHealth Services Accessibilityen
dc.subject.meshHumansen
dc.subject.meshLeishmaniasisen
dc.subject.meshMeningitis, Cryptococcalen
dc.subject.meshTrachomaen
dc.subject.meshWorld Healthen
dc.titlePricing of drugs and donations: options for sustainable equity pricing.en
dc.contributor.departmentCampaign for Access to Essential Medicines, Médecins sans Frontières, Geneva, Switzerland. carmen_perez@madrid.msf.orgen
dc.identifier.journalTropical Medicine & International Healthen
refterms.dateFOA2019-03-04T09:13:16Z
html.description.abstractEffective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines. Increasingly, drug donations have been established by drug companies, but these are often limited in time, place or use. Measures exist which are more sustainable and will have a greater positive impact on people's health. Principally, these are encouraging generic competition; adopting into national legislation and implementing TRIPS safeguards to gain access to cheaper sources of drugs; differential pricing; creating high volume or high demand through global and regional procurement; and supporting the production of quality generic drugs by developing countries through voluntary licenses if needed, and facilitating technology transfer.


Files in this item

Thumbnail
Name:
Perez Trop Med.pdf
Size:
189.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record